Table 1

Baseline characteristics of the patients with cancer and non-cancer control

FactorPD-1B+/Vac+PD-1B-/Vac+PD-1B+/Vac-Total patients with cancerNon-cancer control
Age (years), mean (SD)49.78 (11.38)51.17 (10.42)49.87 (10.66)50.28 (11.15)49.93 (12.28)
GenderMale34 (24.6%)44 (26.8%)38 (25.0%)116 (25.6%)51 (24.7%)
Female104 (75.4%)120 (73.2%)114 (75.0%)338 (74.4%)155 (75.2%)
PathologyNSCLC48 (34.8%)54 (32.9%)55 (36.2%)157 (34.6%)
GI62 (44.9%)72 (43.9%)62 (40.8%)196 (43.2%)
HN28 (20.3%)38 (23.2%)35 (23.0%)101 (22.2%)
ChemotherapyYes28 (20.3%)42 (25.6%)41 (27.0%)111 (24.4%)
No110 (79.7%)122 (74.4%)111 (73.0%)343 (75.6%)
ECOG-PS092 (66.7%)120 (73.2%)107 (70.4%)319 (70.3%)
146 (33.3%)44 (26.8%)45 (29.6%)135 (29.7%)
ICI duration (weeks),
mean (SD)
6.54 (2.30)6.49 (2.31)
MetastasisYes10 (7.2%)12 (7.3%)29 (19.1%)51 (11.2%)
No128 (92.8%)152 (92.7%)123 (80.9%)403 (88.8%)
Dose of vaccine158 (42.0%)72 (43.9%)130 (43.0%)99 (48.0%)
280 (58.0%)92 (56.1%)172 (57.0%)107 (52.0%)
Comorbidity with rheumatic diseaseYes32 (23.2%)40 (24.4%)30 (19.7%)102 (22.5%)40 (19.4%)
No106 (76.8%)124 (75.6%)122 (80.3%)352 (77.5%)166 (89.6%)
  • ECOG-PS, Eastern Cooperative Oncology Group-Performance Score; GI, gastrointestinal cancers; HN, head and neck cancers; ICI, immune checkpoint inhibitor; NSCLC, non-small cell lung cancer; PD-1B, progression cell death-1 blocker; SD, standard deviation; Vac, vaccine.